Exclusive: Jim Wilson startup gets FDA green light for first test of gene editing in babies
04 Apr 2024
Gene Therapy
Nearly 25 years ago, a young man with an inherited liver disease died from a vicious immune reaction to an experimental gene therapy. Now Jim Wilson, the scientist behind that failed treatment, is back with a new attempt to cure the disease, this time by editing the genes of newborns and infants.
Philadelphia-based iEcure, one of several biotech companies spun out of Wilson’s expansive gene therapy program at the University of Pennsylvania, is preparing to treat babies up to 9 months of age with the severest form of the metabolic condition, called ornithine transcarbamylase deficiencyornithine transcarbamylase deficiency.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.